Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2019, Article ID 8107807, 14 pages
https://doi.org/10.1155/2019/8107807
Research Article

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour’s TMPRSS2-ERG Fusion Status

1Philips Research Europe, 5656AE Eindhoven, Netherlands
2Gerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany
3Prostate Center, University Hospital Münster, 48149 Münster, Germany
4Institute of Cardiovascular and Medical Science, University of Glasgow, G12 8TA Glasgow, Scotland, UK
5Institute of Pharmaceutical Science, King’s College London, 150 Stamford Street, London, WC2R 2LS London, UK
6Mironid Ltd, BioCity Scotland, ML1 5UH Newhouse, Scotland, UK
7Department of Urology, 3000CA Erasmus Medical Center, Rotterdam, Netherlands

Correspondence should be addressed to Ralf Hoffmann; moc.spilihp@nnamffoh.flar

Received 27 January 2019; Revised 10 April 2019; Accepted 21 April 2019; Published 2 June 2019

Guest Editor: Anna Ferrari

Copyright © 2019 Dianne van Strijp et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, pp. E359–E386, 2014. View at Publisher · View at Google Scholar
  3. P. C. Albertsen, J. A. Hanley, and J. Fine, “20-Year outcomes following conservative management of clinically localized prostate cancer,” Journal of the American Medical Association, vol. 293, no. 17, pp. 2095–2101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-E. Johansson, O. Andrén, S.-O. Andersson et al., “Natural history of early, localized prostate cancer,” The Journal of the American Medical Association, vol. 291, no. 22, pp. 2713–2719, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Hernandez, M. E. Nielsen, M. Han, and A. W. Partin, “Contemporary evaluation of the d'amico risk classification of prostate cancer,” Urology, vol. 70, no. 5, pp. 931–935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Boorjian, R. J. Karnes, L. J. Rangel, E. J. Bergstralh, and M. L. Blute, “Mayo clinic validation of the d'amico risk group classification for predicting survival following radical prostatectomy,” The Journal of Urology, vol. 179, no. 4, pp. 1354–1361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. Reese, P. M. Pierorazio, and M. Han, “Contemporary evaluation of the national comprehensive cancer network prostate cancer risk classification system,” Urology, vol. 80, no. 5, pp. 1075–1079, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Gandaglia, J. Schiffmann, T. Schlomm et al., “Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: implications for active surveillance candidates selection,” The Prostate, vol. 75, no. 13, pp. 1484–1491, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-W. Jung, J. K. Lee, S. K. Hong, S.-S. Byun, and S. E. Lee, “Stratification of patients with intermediate-risk prostate cancer,” BJU International, vol. 115, no. 6, pp. 907–912, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. F.-J. H. Drost, A. Rannikko, R. Valdagni et al., “Can active surveillance really reduce the harms of overdiagnosing prostate cancer? a reflection of real life clinical practice in the PRIAS study,” Translational Andrology and Urology, vol. 7, no. 1, pp. 98–105, 2018. View at Publisher · View at Google Scholar · View at Scopus
  11. L. P. Bokhorst, R. Valdagni, A. Rannikko et al., “A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment,” European Urology, vol. 70, no. 6, pp. 954–960, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. J. L. Donovan and F. C. Hamdy, “Time for a “radical” change to active surveillance for prostate cancer?” European Urology, vol. 74, no. 3, pp. 281-282, 2018. View at Publisher · View at Google Scholar · View at Scopus
  13. S. A. Tomlins, D. R. Rhodes, S. Perner et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science, vol. 310, no. 5748, pp. 644–648, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Taskén and E. M. Aandahl, “Localized effects of cAMP mediated by distinct routes of protein kinase a,” Physiological Reviews, vol. 84, no. 1, pp. 137–167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. U. Banerjee and X. Cheng, “Exchange protein directly activated by cAMP encoded by the mammalian rapgef3 gene: Structure, function and therapeutics,” Gene, vol. 570, no. 2, pp. 157–167, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Houslay, “Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown,” Trends in Biochemical Sciences, vol. 35, no. 2, pp. 91–100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Böttcher, D. J. P. Henderson, K. Dulla et al., “Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression,” British Journal of Cancer, vol. 113, no. 10, pp. 1502–1511, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. S. C. Baca, D. Prandi, M. S. Lawrence et al., “Punctuated evolution of prostate cancer genomes,” Cell, vol. 153, pp. 666-667, 2013. View at Google Scholar
  19. Z. Wang, Y. Wang, J. Zhang et al., “Significance of the TMRPSS2:ERG gene fusion in prostate cancer,” Molecular Medicine Reports, vol. 16, pp. 5450–5458, 2017. View at Publisher · View at Google Scholar
  20. M. Alves de Inda, D. van Strijp, E. den Biezen-Timmermans et al., “Validation of cyclic adenosine monophosphate phosphodiesterase-4D7 for its independent contribution to risk stratification in a prostate cancer patient cohort with longitudinal biological outcomes,” European Urology Focus, vol. 13, pp. 376–384, 2017. View at Publisher · View at Google Scholar
  21. D. Van Strijp, C. De Witz, P. C. Vos et al., “The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes,” Prostate Cancer and Prostatic Diseases, vol. 2018, Article ID 5821616, 11 pages, 2018. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Cooperberg, D. J. Pasta, E. P. Elkin et al., “The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy,” The Journal of Urology, vol. 173, no. 6, pp. 1938–1942, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. B. S. Taylor, N. Schultz, H. Hieronymus et al., “Integrative genomic profiling of human prostate cancer,” Cancer Cell, vol. 18, no. 1, pp. 11–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Li, V. Ruotti, R. M. Stewart, J. A. Thomson, and C. N. Dewey, “RNA-Seq gene expression estimation with read mapping uncertainty,” Bioinformatics, vol. 26, no. 4, pp. 493–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. J. Vickers, A. M. Cronin, E. B. Elkin, and M. Gonen, “Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers,” BMC Medical Informatics and Decision Making, vol. 8, no. 53, pp. 1–17, 2008. View at Google Scholar · View at MathSciNet
  26. A. J. Vickers, B. Van Calster, and E. W. Steyerberg, “Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests,” BMJ, vol. 25, p. 352, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Böttcher, K. Dulla, D. Van Strijp et al., “Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases,” Oncotarget , vol. 7, no. 43, pp. 70669–70684, 2016. View at Google Scholar · View at Scopus
  28. J. Cheng, J. Demeulemeester, D. C. Wedge et al., “Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors,” Nature Communications, vol. 8, article 1221, 2017. View at Publisher · View at Google Scholar
  29. D. C. Wedge, G. Gundem, T. Mitchell et al., “Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets, routes of progression and drug targets,” Nature Genetics, vol. 50, pp. 682–692, 2018. View at Google Scholar
  30. A. Briganti, N. Fossati, J. W. F. Catto et al., “Active surveillance for low-risk prostate cancer: the european association of urology position in 2018,” European Urology, vol. 74, pp. 357–368, 2018. View at Google Scholar
  31. F. C. Hamdy, J. L. Donovan, J. A. Lane et al., “10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer,” The New England Journal of Medicine, vol. 375, no. 15, pp. 1415–1424, 2016. View at Publisher · View at Google Scholar
  32. J. T. Eineluoto, P. Järvinen, A. Kenttämies et al., “Repeat multiparametric MRI in prostate cancer patients on active surveillance,” PLoS ONE, vol. 12, no. 12, p. e0189272, 2017. View at Publisher · View at Google Scholar
  33. S. Canfield, M. J. Kemeter, J. Hornberger, and P. G. Febbo, “Surveillance use among a low-risk prostate cancer population in a large US payer system: 17-gene genomic prostate score versus other risk stratification methods,” Reviews in Urology, vol. 19, pp. 203–212, 2017. View at Google Scholar
  34. K. A. Keegan, M. A. Dall'Era, B. Durbin-Johnson, and C. P. Evans, “Active surveillance for prostate cancer compared with immediate treatment: An economic analysis,” Cancer, vol. 118, no. 14, pp. 3512–3518, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Dall'Era, “The economics of active surveillance for prostate cancer,” Current Urology Reports, vol. 23, pp. 278–282, 2013. View at Publisher · View at Google Scholar